Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 833 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Cancer Patients Get Free, Beautiful Henna Crowns From Local Artist March 17, 2020 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small... November 21, 2020 EMA Recommends Extension of Indications for Enzalutamide April 2, 2021 Load more HOT NEWS Daratumumab Plus Bortezomib and Dexamethasone Regimen Significantly Prolongs OS in Patients... New treatment for Waldenstrom’s macroglobulinaemia in England Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with...
